Pharmion, Cabrellis deal

PHRM acquired Cabrellis for $59 million in cash. The deal gives PHRM North American and European rights to amrubicin, a third-generation synthetic anthracycline that is in Phase II testing to

Read the full 303 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE